A “last word” from the Genitourinary Cancers Symposium

Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE

4- and 5-year outcomes after SBRT for localized prostate cancer

Two posters presented today at the Genitourinary Cancers Symposium have extended our knowledge about outcomes after stereotactic body radiation therapy (SBRT or CyberKnife therapy) for localized disease. … READ MORE …

5-year data on treatment of low-risk patients with SBRT

A new article in Radiation Oncology provides initial 5-year outcomes of patients treated with stereotactic body radiation therapy (SBRT), also known as CyberKnife therapy. … READ MORE …

Medicare advisors discuss radiation therapy for prostate cancer

Reuters has published a summary report on the discussions of a Medicare advisory panel (MedCAC) held yesterday to address the value of different types of radiation therapy in the treatment of early-stage prostate cancer. … READ MORE …

Data from a 300+ patient series treated with CyberKnife

Stereotactic body radiotherapy (SBRT) — aka CyberKnife radiotherapy — is among the most recent methods developed for the treatment of prostate cancer using radiation. People have been waiting a while now to see early data from a large series of patients. … READ MORE …

Prostate cancer news reports: Thursday, February 18, 2010

Today’s news reports include commentary on studies dealing with:

  • Whether RALP outcomes are really comparable to those from RRP
  • Surgical expertise, surgical caseload, and pelvic lymphadenectomy in treatment of intermediate- and high-risk prostate cancer
  • Sexual function after first-line treatment with SBRT (CyberKnife)
  • Distinguishing true biochemical recurrence from a PSA “bounce” after 125I-based prostate brachytherapy … READ MORE …

What cost prostate cancer treatment?

Many readers will be interested in the article titled “Debate surrounds new prostate-cancer treatment” that appeared today in the Philadelphia Inquirer on the topic of prostate cancer treatment costs. … READ MORE …

Stereotactic body radiation: early data from a trial of CyberKnife therapy

The ‘New” Prostate Cancer InfoLink has previously stated the importance of having more data about the potential of CyberKnife therapy in the treatment of localized prostate cancer. The first such data are now available. … READ MORE …

Advances in external beam radiotherapy for treatment of localized prostate cancer

In the past year or so there have been three significant technological advances in the use of external beam radiotherapy for the treatment of localized prostate cancer, and we want to be sure that the patient community is both aware of and understands the limitations of these technological advances. … READ MORE …

The regional vagaries of Medicare coverage (in the USA)

An article in today’s New York Times addresses an issue of potentially growing importance for Medicare beneficiaries with prostate cancer. Is the form of treatment you want covered where you live? … READ MORE …

Cyberknives, efficacy, safety, and money

An article in the Washington Post, published last Friday, offers some interesting insights into the current glut of information about the potential for Cyberknife radiation therapy in the treatment of prostate cancer. This is an issue on which we first commented back in July. … READ MORE …

CyberKnife “robotic radiosurgery” for localized prostate cancer …

… Are we getting things out of proportion?

The CyberKnife® system  was initially developed as a method to treat tumors in places like the brain that were inaccessible to physical surgery, and was originally approved by the FDA in 1992. Now it is being touted as “the next thing” in “radiosurgery” for prostate cancer. … MORE …